Company: CRVO
Filing Date: 2025-03-10
Form Type: 8-K
Source: 0001437749-25-006832
Chunk: 0

Company: CervoMed Inc.
Filing Date: 2025-03-10
Form: 8-K
Item: Item 7.01
Chunk 0
---
Item 7.01

Regulation FD Disclosure

Press Release

On March 10, 2025, CervoMed Inc. (the “ Company”) issued a press release announcing positive results from the first sixteen weeks of the open-label extension phase of the RewinD-LB Phase 2b clinical trial of neflamapimod in patients with dementia with Lewy bodies. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

The information in this Item 7.01 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 8.01Other Events